Pharmacovigilance Risk Assessment Committee (PRAC)
Draft agenda for the meeting on 26-29 October 2020

Chair: Sabine Straus – Vice-Chair: Martin Huber

26 October 2020, 10:30 – 19:30, via teleconference
27 October 2020, 08:30 – 19:30, via teleconference
28 October 2020, 08:30 – 19:30, via teleconference
29 October 2020, 08:30 – 16:00, via teleconference

Organisational, regulatory and methodological matters (ORGAM)
12 November 2020, 09:00 – 12:00, via teleconference

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised.

Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1).
Table of contents

1. Introduction 10

1.1. Welcome and declarations of interest of members, alternates and experts ........ 10
1.2. Agenda of the meeting on 26-29 October 2020 ............................................. 10
1.3. Minutes of the previous meeting on 28 September-01 October 2020 ............... 10

2. EU referral procedures for safety reasons: urgent EU procedures 10

2.1. Newly triggered procedures ......................................................................... 10
2.2. Ongoing procedures ....................................................................................... 10
2.3. Procedures for finalisation .............................................................................. 10

3. EU referral procedures for safety reasons: other EU referral procedures 10

3.1. Newly triggered procedures ......................................................................... 10
3.2. Ongoing procedures ....................................................................................... 10
3.2.1. Ifosfamide (NAP) - EMEA/H/A-31/1495 ..................................................... 10
3.3. Procedures for finalisation .............................................................................. 11
3.4. Re-examination procedures .......................................................................... 11
3.5. Others ............................................................................................................ 11

4. Signals assessment and prioritisation 11

4.1. New signals detected from EU spontaneous reporting systems................. 11
4.1.1. Immune checkpoint inhibitors: atezolizumab – TECENTRIQ (CAP); avelumab – BAVENCIO (CAP); cemiplimab – LIBTAYO (CAP); durvalumab – IMFINZI (CAP); ipilimumab – YERVOY (CAP); pembrolizumab – KEYTRUDA (CAP); nivolumab - OPDIVO (CAP) .................................................. 11
4.2. New signals detected from other sources ..................................................... 11
4.2.1. Cannabidiol – EPIDYOLEX (CAP); tacrolimus - ADVAGRAF (CAP), ENVARSUS (CAP), MODIGRAF (CAP), TACFORIUS (CAP); NAP ................................................................................. 11
4.2.2. Trastuzumab emtansine – KADCYLA (CAP) ............................................. 12
4.3. Signals follow-up and prioritisation ............................................................... 12
4.3.1. Anakinra - KINERET (CAP) - EMEA/H/C/000363/SDA/032; canakinumab - ILARIS (CAP) - EMEA/H/C/001109/SDA/054 ................................................................................. 12
4.3.2. Cefepime (NAP) ......................................................................................... 12
4.3.3. Ceftriaxone (NAP) ..................................................................................... 12
4.3.4. Dabrafenib - TAFINLAR (CAP) - EMEA/H/C/002604/SDA/018; trametinib - MEKINIST (CAP) - EMEA/H/C/002643/SDA/013 ................................................................. 13
4.3.5. Ibrutinib - IMBRUVICA (CAP) - EMEA/H/C/003791/SDA/031 .................. 13
4.3.7. Lamotrigine (NAP) ................................................................................................... 13

4.4. Variation procedure(s) resulting from signal evaluation ...................................... 14
4.4.1. Baricitinib - OOLUMIANT (CAP) - EMEA/H/C/004085/II/0019 .............................. 14

5. Risk management plans (RMPs) 14

5.1. Medicines in the pre-authorisation phase ............................................................. 14
5.1.1. Adalimumab - EMEA/H/C/005188 ................................................................. 14
5.1.2. Bevacizumab - EMEA/H/C/005640 ............................................................... 14
5.1.3. Estetrol, drospirenone - EMEA/H/C/005336 ................................................... 14
5.1.4. Estetrol, drospirenone - EMEA/H/C/005382 .................................................... 14
5.1.5. Lisocabtagene maraleucel - EMEA/H/C/004731, Orphan ............................... 15
5.1.6. Risdiplam - EMEA/H/C/005145, Orphan ....................................................... 15

5.2. Medicines in the post-authorisation phase – PRAC-led procedures ....................... 15
5.2.1. Agomelatine - THYMANAX (CAP) - EMEA/H/C/000916/WS1849/0045; VALDOXAN (CAP) - EMEA/H/C/000915/WS1849/0047 .............................................................. 15
5.2.2. Histamine dihydrochloride - CEPLENE (CAP) - EMEA/H/C/000796/II/0040 .......... 15
5.2.3. Iloprost - VENTAVIS (CAP) - EMEA/H/C/000474/II/0066 .............................. 16
5.2.4. Mannitol - BRONCHITOL (CAP) - EMEA/H/C/001252/II/0042, Orphan ............. 16
5.2.5. Pramipexole - MIRAPEXIN (CAP) - EMEA/H/C/000134/WS1897/0087 .............. 16
5.2.6. Tacrolimus - ADVAGRAF (CAP) - EMEA/H/C/000712/WS1805/0057; MODIGRAF (CAP) - EMEA/H/C/000954/WS1805/0035; NAP .............................................................. 17
5.2.7. Tolvaptan - JINARC (CAP) - EMEA/H/C/002788/II/0029 .............................. 17
5.2.8. Trabectedin - YONDELIS (CAP) - EMEA/H/C/000773/II/0061 .......................... 17
5.2.9. Umeclidinium bromide - INCRUSE ELLIPTA (CAP) - EMEA/H/C/002809/WS1589/0029; ROLUFTA ELLIPTA (CAP) - EMEA/H/C/004654/WS1589/0014 .......... 18

5.3. Medicines in the post-authorisation phase – CHMP-led procedures ..................... 18
5.3.1. Avatrombopag - DOPTELET (CAP) - EMEA/H/C/004722/II/0004/G .................. 18
5.3.2. Beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium - TRIMBOW (CAP) - EMEA/H/C/004257/X/0008/G ................................................ 18
5.3.3. Belatacept - NULOJIX (CAP) - EMEA/H/C/002098/II/0070 ............................ 19
5.3.4. Carfilzomib - KYPROLIS (CAP) - EMEA/H/C/003985/WS1840/0089 ............... 20
5.3.5. Fluticasone furoate, umecclidinium, vilanterol - ELEBRATO ELLIPTA (CAP) - EMEA/H/C/004363/X/0012/G ................................................................. 20
5.3.6. Fluticasone furoate, umecclidinium, vilanterol - TEMYBRIC ELLIPTA (CAP) - EMEA/H/C/002556/II/0058/G ................................................................. 21
5.3.7. Fluticasone furoate, umecclidinium, vilanterol - TRELEGY ELLIPTA (CAP) - EMEA/H/C/004363/X/0012/G ................................................................. 20
5.3.8. Follitropin delta - REKOVELLE (CAP) - EMEA/H/C/003994/II/0022 .................. 20
5.3.9. Ipilimumab - YERVOY (CAP) - EMEA/H/C/002950/WS1840/0084; nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/WS1840/0089 ................................. 20
5.3.10. Lacosamide - LACOSAMIDE ACCORD (CAP) - EMEA/H/C/004443/X/0007 ....... 20
5.3.11. Lipegfilgrastim - LONIQUE (CAP) - EMEA/H/C/002556/II/0058/G .................. 20

Pharmacovigilance Risk Assessment Committee (PRAC)
EMAPRAC/570668/2020
5.3.12. Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/X/0116 ........................................ 21
5.3.13. Nintedanib - VARGATEF (CAP) - EMEA/H/C/002569/II/0035/G .................................. 21
5.3.14. Ocrelizumab - OCREVUS (CAP) - EMEA/H/C/004043/II/0021 .................................. 21
5.3.15. Pegvisomant - SOMAVERT (CAP) - EMEA/H/C/000409/II/0098/G ......................... 22
5.3.16. Rituximab - BLITZIMA (CAP) - EMEA/H/C/004723/WS1893/0034; RITEMVIA (CAP) - EMEA/H/C/004725/WS1893/0034; TRUXIMA (CAP) - EMEA/H/C/004112/WS1893/0037 ... 22
5.3.17. Rivaroxaban - XARELTO (CAP) - EMEA/H/C/000944/X/0074/G .............................. 22
5.3.18. Rucaparib - RUBRACA (CAP) - EMEA/H/C/004272/II/0020 ....................................... 23
5.3.20. Sodium phenylbutyrate - PHEBURANE (CAP) - EMEA/H/C/002500/X/0026 ............ 23
5.3.21. Sodium phenylbutyrate - PHEBURANE (CAP) - EMEA/H/C/002500/X/0028 ............ 24
5.3.22. Stiripentol - DIACOMIT (CAP) - EMEA/H/C/000664/X/0032 ...................................... 24

6. Periodic safety update reports (PSURs) ................................................................. 24

6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only ............................................................................................................... 24

6.1.1. Abemaciclib - VERZENIOS (CAP) - PSUSA/00010724/202003 .................................. 24
6.1.2. Alogliptin - VIPIDIA (CAP); alogliptin, metformin - VIPDOMET (CAP); alogliptin, pioglitazone - INRESYNC (CAP) - PSUSA/00010061/202004 ........................................ 24
6.1.3. Avelumab - BAVENCIO (CAP) - PSUSA/00010635/202003 ........................................ 24
6.1.4. Brolucizumab - BEOVU (CAP) - PSUSA/00010829/202004 ........................................ 25
6.1.5. Canagliflozin - INVOKANA (CAP); canagliflozin, metformin - VOKANAMET (CAP) - PSUSA/00010077/202003 ........................................................... 25
6.1.6. Cemiplimab - LIBTAYO (CAP) - PSUSA/00010780/202003 .......................................... 25
6.1.7. Certolizumab - CIMZIA (CAP) - PSUSA/00000624/202003 .......................................... 25
6.1.8. Dacomitinib - VIZIMPRO (CAP) - PSUSA/00010757/202003 ...................................... 25
6.1.9. Dapagliflozin - EDISTRIDE (CAP); FORXIGA (CAP) - PSUSA/00010029/202004 ......... 25
6.1.10. Darvadstrocel - ALOFISEL (CAP) - PSUSA/00010676/202003 ..................................... 26
6.1.11. Dupilumab - DUPIXENT (CAP) - PSUSA/00010645/202003 ...................................... 26
6.1.12. Emtricitabine - EMTRIVA (CAP) - PSUSA/00001210/202004 ................................. 26
6.1.13. Emtricitabine, tenofovir alafenamide - DESCOVY (CAP) - PSUSA/00010515/202004 .... 26
6.1.15. Exenatide - BYDUREON (CAP); BYETTA (CAP) - PSUSA/00009147/202003 .............. 26
6.1.16. Fostamatinib - TAVLESSE (CAP) - PSUSA/00010819/202004 ................................. 27
6.1.17. Galcanezumab - EMGALITY (CAP) - PSUSA/00010733/202003 ............................ 27
6.1.18. Gilteritinib - XOSPATA (CAP) - PSUSA/00010832/202003 ....................................... 27
6.1.19. Herpes zoster vaccine (recombinant, adjuvanted) - SHINGRIX (CAP) - PSUSA/00010678/202004 ............................................................................................................................. 27
6.1.20. Histamine - CEPLENE (CAP) - PSUSA/00001610/202004 ........................................ 27
6.1.21. Insulin glulisine - APIDRA (CAP) - PSUSA/00001752/202004 ................................. 27
6.1.22. Ipilimumab - YERVOY (CAP) - PSUSA/00009200/202003 ....................................... 28
6.1.23. Ixekizumab - TALTZ (CAP) - PSUSA/00010493/202003 ................................................ 28
6.1.24. Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202003 ........................................... 28
6.1.25. Lusutrombopag - MULPLEO (CAP) - PSUSA/00010755/202003 .................................. 28
6.1.27. Mogamulizumab - POTELIGEO (CAP) - PSUSA/00010741/202003 .................................. 28
6.1.28. Naldemedine - RIZMOIC (CAP) - PSUSA/00010753/202003 ........................................ 29
6.1.29. Nintedanib - OFEV (CAP) - PSUSA/00010655/202003 .................................................. 29
6.1.30. Niraparib - ZEJULA (CAP) - PSUSA/00010662/202003 .................................................. 29
6.1.31. Ocrelizumab - OCREVUS (CAP) - PSUSA/00010662/202003 ...................................... 29
6.1.32. Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202003 .......................................... 29
6.1.33. Sodium zirconium cyclosilicate - LOKELMA (CAP) - PSUSA/00010675/202003 ................. 30
6.1.34. Talazoparib - TALZENNA (CAP) - PSUSA/00010781/202004 .......................................... 30
6.1.35. Trifluridine, tipiracil - LONSURF (CAP) - PSUSA/00010517/202003 ............................. 30
6.1.36. Vandetanib - CAPRELSA (CAP) - PSUSA/00009327/202004 ....................................... 30
6.1.37. Yttrium (90Y) chloride - YTRACIS (CAP); YTTRIGA (CAP) - PSUSA/00003137/202003 ...... 30
6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs) .......................................................... 31
6.2.1. Enoxaparin - INHIXA (CAP); NAP - PSUSA/00010833/202004 ........................................... 31
6.2.2. Tenofovir disoproxil - TENOFOVIR DISOPROXIL MYLAN (CAP); TENOFOVIR DISOPROXIL ZENTIVA (CAP); VIREAD (CAP); NAP - PSUSA/00002892/202003 .................. 31
6.2.3. Zonisamide - ZONEGRAN (CAP); NAP - PSUSA/00003152/202003 ................................. 31
6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only ........................................................................................................... 31
6.3.1. Ascorbic acid, paracetamol, pheniramine maleate (NAP) - PSUSA/00002368/202003 ....... 31
6.3.2. Ethosuximide (NAP) - PSUSA/00001316/202003 ............................................................ 31
6.3.3. Fluconazole (NAP) - PSUSA/00001404/202003 ............................................................ 32
6.3.4. Flucloxacillin (NAP) - PSUSA/00001402/202003 .......................................................... 32
6.3.5. Galantamine (NAP) - PSUSA/00001512/202003 .......................................................... 32
6.3.6. Hydroxyethyl starch (HES) (NAP) - PSUSA/00001694/202003 ....................................... 32
6.3.7. Lanthanum (NAP) - PSUSA/00003175/202003 ............................................................ 32
6.3.8. Metamizole (NAP) - PSUSA/00003005/202003 ............................................................ 33
6.3.9. Trandolapril, verapamil (NAP) - PSUSA/00003005/202003 ............................................ 33
6.4. Follow-up to PSUR/PSUSA procedures ......................................................................... 33
6.4.1. Lenalidomide - REVLIMID (CAP) - EMEA/H/C/000717/LEG 050 ................................. 33
6.5. Variation procedure(s) resulting from PSUSA evaluation ............................................ 33
6.5.1. Ixazomib - NINLARO (CAP) - EMEA/H/C/003844/II/0022, Orphan ......................... 33
6.6. Expedited summary safety reviews ............................................................................ 33
# Post-authorisation safety studies (PASS)

## 7. Post-authorisation safety studies (PASS)

### 7.1. Protocols of PASS imposed in the marketing authorisation(s)

<table>
<thead>
<tr>
<th>Product</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betibeglogene autotemcel - ZYNTEGLO (CAP)</td>
<td>EMEA/H/C/PSA/S/0059</td>
</tr>
<tr>
<td>Eliglustat - CERDELGA (CAP)</td>
<td>EMEA/H/C/PSA/S/0054.1</td>
</tr>
<tr>
<td>Methylphenidate hydrochloride (NAP)</td>
<td>EMEA/H/N/PSP/S/0064.5</td>
</tr>
<tr>
<td>Parathyroid hormone – NATPAR (CAP)</td>
<td>EMEA/H/C/PSA/S/0053.1</td>
</tr>
</tbody>
</table>

### 7.2. Protocols of PASS non-imposed in the marketing authorisation(s)

<table>
<thead>
<tr>
<th>Product</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betibeglogene autotemcel - ZYNTEGLO (CAP)</td>
<td>EMEA/H/C/PSA/S/0059</td>
</tr>
<tr>
<td>Eliglustat - CERDELGA (CAP)</td>
<td>EMEA/H/C/PSA/S/0054.1</td>
</tr>
<tr>
<td>Methylphenidate hydrochloride (NAP)</td>
<td>EMEA/H/N/PSP/S/0064.5</td>
</tr>
<tr>
<td>Parathyroid hormone – NATPAR (CAP)</td>
<td>EMEA/H/C/PSA/S/0053.1</td>
</tr>
</tbody>
</table>

### 7.3. Results of PASS imposed in the marketing authorisation(s)

### 7.4. Results of PASS non-imposed in the marketing authorisation(s)

### 7.5. Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation

<table>
<thead>
<tr>
<th>Product</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab - IMRALDI (CAP)</td>
<td>EMEA/H/C/004279/MEA 003</td>
</tr>
<tr>
<td>Adalimumab - IMRALDI (CAP)</td>
<td>EMEA/H/C/004279/MEA 004</td>
</tr>
<tr>
<td>Belimumab - BENLYSTA (CAP)</td>
<td>EMEA/H/C/002015/MEA 003.4</td>
</tr>
<tr>
<td>Damoctocog alfa pegol - JIVI (CAP)</td>
<td>EMEA/H/C/004054/MEA 003.1</td>
</tr>
<tr>
<td>Dimethyl fumarate - SKILARENCY (CAP)</td>
<td>EMEA/H/C/002157/MEA 001.4</td>
</tr>
</tbody>
</table>

Pharmacovigilance Risk Assessment Committee (PRAC)
EMA/PRAC/570668/2020

Page 6/51
7.5.6. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/MEA 007.5 .............................................. 41
7.5.7. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/MEA 026.8 .............................................. 41
7.5.8. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 004.8 ................................ 41
7.5.9. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 003.5 .............................. 42
7.5.10. Simoctocog alfa - NUWIQ (CAP) - EMEA/H/C/002813/MEA 004.6 ........................................ 42
7.5.11. Simoctocog alfa - VIHUMA (CAP) - EMEA/H/C/004459/MEA 004.5 ....................................... 42
7.5.12. Ulipristal acetate - ESMYA (CAP) - EMEA/H/C/002041/MEA 001.1 ........................................ 43
7.5.13. Vedolizumab - ENTYVIO (CAP) - EMEA/H/C/002782/MEA 001.1 ........................................ 43
7.6. Others .......................................................................................................................................... 43
7.7. New Scientific Advice .................................................................................................................. 43
7.8. Ongoing Scientific Advice ........................................................................................................... 43
7.9. Final Scientific Advice (Reports and Scientific Advice letters) .................................................. 43

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments 43
8.1. Annual reassessments of the marketing authorisation ................................................................. 43
8.1.1. Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/S/0028 (without RMP) .............. 43
8.1.2. Galsulfase - NAGLAZYME (CAP) - EMEA/H/C/000640/S/0083 (without RMP) .................... 43
8.1.3. Nelarabine - ATRIANCE (CAP) - EMEA/H/C/000752/S/0051 (without RMP) ...................... 44
8.1.4. Smallpox vaccine (live modified vaccinia virus Ankara) - IMVANEX (CAP) -
      EMEA/H/C/002596/S/0054 (without RMP) .............................................................................. 44
8.1.5. Vestronidase alfa - MEPSEVII (CAP) - EMEA/H/C/004438/S/0017 (without RMP) .............. 44
8.2. Conditional renewals of the marketing authorisation ................................................................. 44
8.2.1. Bedaquiline - SIRTURO (CAP) - EMEA/H/C/002614/R/0040 (without RMP) ....................... 44
8.2.2. Obeticholic acid - OCALIVA (CAP) - EMEA/H/C/004093/R/0023 (without RMP) ............... 44
8.3. Renewals of the marketing authorisation ...................................................................................... 44
8.3.1. Albutrepenonacog alfa - IDELVION (CAP) - EMEA/H/C/003955/R/0047 (without RMP) ...... 44
8.3.2. Amlodipine, valsartan - AMLODIPINE-VALSARTAN MYLAN (CAP) - EMEA/H/C/004037/R/0008
      (with RMP) .......................................................................................................................... 45
8.3.3. Apixaban - ELIQUIS (CAP) - EMEA/H/C/002148/R/0077 (without RMP) ........................... 45
8.3.4. Emtricitabine, rilpivirine, tenofovir alafenamide - ODEFSEY (CAP) - EMEA/H/C/004156/R/0049
      (with RMP) .......................................................................................................................... 45
8.3.5. Emtricitabine, tenofovir alafenamide - DESCOVY (CAP) - EMEA/H/C/004094/R/0051 (without
      RMP) .................................................................................................................................. 45
8.3.6. Infliximab - FLIXABI (CAP) - EMEA/H/C/004020/R/0064 (without RMP) ......................... 45
8.3.7. Migalastat - GALAFOLD (CAP) - EMEA/H/C/004059/R/0027 (with RMP) ......................... 45

9. Product related pharmacovigilance inspections 46
9.1. List of planned pharmacovigilance inspections ............................................................................. 46
9.2. Ongoing or concluded pharmacovigilance inspections ................................................................. 46
9.3. Others .......................................................................................................................................... 46
# Other safety issues for discussion requested by the CHMP or the EMA

## 10.1. Safety related variations of the marketing authorisation

## 10.2. Timing and message content in relation to Member States’ safety announcements

## 10.3. Other requests

## 10.4. Scientific Advice

# Other safety issues for discussion requested by the Member States

## 11.1. Safety related variations of the marketing authorisation

## 11.2. Other requests

# Organisational, regulatory and methodological matters

## 12.1. Mandate and organisation of the PRAC

## 12.2. Coordination with EMA Scientific Committees or CMDh-v

## 12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

## 12.4. Cooperation within the EU regulatory network

### 12.4.1. Coronavirus (COVID-19) pandemic - update

### 12.4.2. Coronavirus (COVID-19) pandemic – pharmacovigilance initiatives: preparedness plan and coverage data gathering

### 12.4.3. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) steering group – Call for expression of interest for a PRAC representative

## 12.5. Cooperation with International Regulators

## 12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

## 12.7. PRAC work plan

## 12.8. Planning and reporting

### 12.8.1. EU Pharmacovigilance system – quarterly workload measures and performance indicators – Q3 2020 and predictions

## 12.9. Pharmacovigilance audits and inspections

### 12.9.1. Pharmacovigilance systems and their quality systems

### 12.9.2. Pharmacovigilance inspections

### 12.9.3. Pharmacovigilance audits

## 12.10. Periodic safety update reports (PSURs) & Union reference date (EURD) list

### 12.10.1. Periodic safety update reports

### 12.10.2. Granularity and Periodicity Advisory Group (GPAG)

### 12.10.3. PSURs repository

### 12.10.4. Union reference date list – consultation on the draft list

### 12.10.5. Union reference date (EURD) list: EURD tool - update

## 12.11. Signal management


## 12.12. Adverse drug reactions reporting and additional reporting
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.12.1.</td>
<td>Management and reporting of adverse reactions to medicinal products</td>
<td>49</td>
</tr>
<tr>
<td>12.12.2.</td>
<td>Additional monitoring</td>
<td>49</td>
</tr>
<tr>
<td>12.12.3.</td>
<td>List of products under additional monitoring – consultation on the draft list</td>
<td>49</td>
</tr>
<tr>
<td><strong>12.13.</strong></td>
<td>EudraVigilance database</td>
<td>49</td>
</tr>
<tr>
<td>12.13.1.</td>
<td>Activities related to the confirmation of full functionality</td>
<td>49</td>
</tr>
<tr>
<td><strong>12.14.</strong></td>
<td>Risk management plans and effectiveness of risk minimisations</td>
<td>49</td>
</tr>
<tr>
<td>12.14.2.</td>
<td>Risk management systems</td>
<td>49</td>
</tr>
<tr>
<td>12.14.3.</td>
<td>Tools, educational materials and effectiveness measurement of risk minimisations</td>
<td>49</td>
</tr>
<tr>
<td><strong>12.15.</strong></td>
<td>Post-authorisation safety studies (PASS)</td>
<td>50</td>
</tr>
<tr>
<td>12.15.1.</td>
<td>Post-authorisation Safety Studies – imposed PASS</td>
<td>50</td>
</tr>
<tr>
<td>12.15.2.</td>
<td>Post-authorisation Safety Studies – non-imposed PASS</td>
<td>50</td>
</tr>
<tr>
<td><strong>12.16.</strong></td>
<td>Community procedures</td>
<td>50</td>
</tr>
<tr>
<td>12.16.1.</td>
<td>Referral procedures for safety reasons</td>
<td>50</td>
</tr>
<tr>
<td><strong>12.17.</strong></td>
<td>Renewals, conditional renewals, annual reassessments</td>
<td>50</td>
</tr>
<tr>
<td><strong>12.18.</strong></td>
<td>Risk communication and transparency</td>
<td>50</td>
</tr>
<tr>
<td>12.18.1.</td>
<td>Public participation in pharmacovigilance</td>
<td>50</td>
</tr>
<tr>
<td>12.18.2.</td>
<td>Safety communication</td>
<td>50</td>
</tr>
<tr>
<td><strong>12.19.</strong></td>
<td>Continuous pharmacovigilance</td>
<td>50</td>
</tr>
<tr>
<td>12.19.1.</td>
<td>Incident management</td>
<td>50</td>
</tr>
<tr>
<td><strong>12.20.</strong></td>
<td>Others</td>
<td>50</td>
</tr>
<tr>
<td>12.20.1.</td>
<td>Good Pharmacovigilance Practice (GVP) - update on GVP status overview – planning for 2021</td>
<td>50</td>
</tr>
<tr>
<td>12.20.2.</td>
<td>Strategy on measuring the impact of pharmacovigilance – PRAC interest group (IG) Impact – Revised process for prioritising impact research topics</td>
<td>50</td>
</tr>
</tbody>
</table>

**13.** Any other business | 50

**14.** Explanatory notes | 51
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary session to be held 26-29 October 2020. See November 2020 PRAC minutes (to be published post December 2020 PRAC meeting).

1.2. **Agenda of the meeting on 26-29 October 2020**

*Action*: For adoption

1.3. **Minutes of the previous meeting on 28 September-01 October 2020**

*Action*: For adoption

2. **EU referral procedures for safety reasons: urgent EU procedures**

2.1. **Newly triggered procedures**

None

2.2. **Ongoing procedures**

None

2.3. **Procedures for finalisation**

None

3. **EU referral procedures for safety reasons: other EU referral procedures**

3.1. **Newly triggered procedures**

None

3.2. **Ongoing procedures**

3.2.1. **Ifosfamide**¹ (NAP) - EMEA/H/A-31/1495

*Applicant(s)*: various

PRAC Rapporteur: Martin Huber; PRAC Co-rapporteur: Nikica Mirošević Skvrce

¹ Solution, concentrate for solution
Scope: Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

**Action:** For adoption of a PRAC list of outstanding issues (LoOI)

### 3.3. Procedures for finalisation

None

### 3.4. Re-examination procedures

None

### 3.5. Others

None

### 4. Signals assessment and prioritisation

#### 4.1. New signals detected from EU spontaneous reporting systems

**4.1.1.** Immune checkpoint inhibitors:
- atezolizumab – TECENTRIQ (CAP);
- avelumab – BAVENCIO (CAP);
- cemiplimab – LIBTAYO (CAP);
- durvalumab – IMFINZI (CAP);
- ipilimumab – YERVOY (CAP);
- pembrolizumab – KEYTRUDA (CAP);
- nivolumab - OPDIVO (CAP)

Applicant(s): AstraZeneca AB (Imfinzi), Bristol-Myers Squibb Pharma (Opdivo, Yervoy), Merck Europe B.V. (Bavencio), Merck Sharp & Dohme B.V. (Keytruda), Regeneron Ireland Designated (Libtayo), Roche Registration GmbH (Tecentriq)

PRAC Rapporteur: To be appointed

Scope: Signal of immune-mediated cystitis

**Action:** For adoption of PRAC recommendation

EPITT 19610 – New signal

Lead Member State(s): DE, DK, NL, NO, PT

#### 4.2. New signals detected from other sources

**4.2.1.** Cannabidiol – EPIDYOLEX (CAP); tacrolimus – ADVAGRAF (CAP), ENVARSUS (CAP), MODIGRAF (CAP), TACFORIUS (CAP); NAP

Applicant(s): Astellas Pharma Europe B.V. (Advagraf, Modigraf), Chiesi Farmaceutici S.p.A. (Envarsus), GW Pharma (International) B.V. (Epidyolex), Teva B.V. (Tacforius), various

PRAC Rapporteur: To be appointed

---

2 Re-examination of PRAC recommendation under Article 32 of Directive 2001/83/EC
3 Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required
4 For systemic use only
Scope: Signal of drug interaction with cannabidiol leading to tacrolimus serum level increased and toxicity

**Action:** For adoption of PRAC recommendation

EPIT 19614 – New signal

Lead Member State(s): IE, PT, SE

### 4.2.2. Trastuzumab emtansine – KADCYLA (CAP)

Applicant(s): Roche Registration GmbH

PRAC Rapporteur: Hans Christian Siersted

Scope: Signal of extravasation and epidermal necrosis

**Action:** For adoption of PRAC recommendation

EPIT 19611 – New signal

Lead Member State(s): DK

### 4.3. Signals follow-up and prioritisation

#### 4.3.1. Anakinra - KINERET (CAP) - EMEA/H/C/000363/SDA/032; canakinumab - ILARIS (CAP) - EMEA/H/C/001109/SDA/054

Applicant(s): Novartis Europharm Limited (Ilaris), Swedish Orphan Biovitrum AB (publ) (Kineret)

PRAC Rapporteur: Hans Christian Siersted

Scope: Signal of drug reaction with eosinophilia and systemic symptoms (DRESS)

**Action:** For adoption of PRAC recommendation

EPIT 19566 – Follow-up to July 2020

#### 4.3.2. Cefepime (NAP)

Applicant(s): various

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Signal of drug reaction with eosinophilia and systemic symptoms (DRESS)

**Action:** For adoption of PRAC recommendation

EPIT 17866 – Follow-up to June 2020

#### 4.3.3. Ceftriaxone (NAP)

Applicant(s): various

PRAC Rapporteur: Zane Neikena

Scope: Signal of encephalopathy

**Action:** For adoption of PRAC recommendation

EPIT 19492 – Follow-up to April 2020
4.3.4. Dabrafenib - TAFINLAR (CAP) - EMEA/H/C/002604/SDA/018; trametinib - MEKINIST (CAP) - EMEA/H/C/002643/SDA/013

Applicant(s): Novartis Europharm Limited
PRAC Rapporteur: David Olsen
Scope: Signal of sarcoidosis
Action: For adoption of PRAC recommendation
EPITT 19574 – Follow-up to July 2020

4.3.5. Ibrutinib - IMBRUVICA (CAP) - EMEA/H/C/003791/SDA/031

Applicant(s): Janssen-Cilag International NV
PRAC Rapporteur: Nikica Mirošević Skvrce
Scope: Signal of hepatitis E
Action: For adoption of PRAC recommendation
EPITT 19569 – Follow-up to July 2020

4.3.6. Immune checkpoint inhibitors:

Applicant(s): AstraZeneca AB (Imfinzi), Bristol-Myers Squibb Pharma (Opdivo, Yervoy), Merck Europe B.V. (Bavencio), Merck Sharp & Dohme B.V. (Keytruda), Regeneron Ireland Designated (Libtayo), Roche Registration GmbH (Tecentriq)
PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: Signal of eosinophilic fasciitis
Action: For adoption of PRAC recommendation
EPITT 19567 – Follow-up to June 2020

4.3.7. Lamotrigine (NAP)

Applicant(s): various
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Signal of photosensitivity
Action: For adoption of PRAC recommendation
EPITT 19548 – Follow-up to March 2020
4.4. Variation procedure(s) resulting from signal evaluation

4.4.1. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/II/0019

Applicant: Eli Lilly Nederland B.V.
PRAC Rapporteur: Adam Przybylkowski

Scope: Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on diverticulitis following the recommendation of signal procedure SDA/010 (EPITT 19496) adopted in May 2020. The package leaflet is updated accordingly

Action: For adoption of PRAC Assessment Report

5. Risk management plans (RMPs)

5.1. Medicines in the pre-authorisation phase

5.1.1. Adalimumab - EMEA/H/C/005188

Scope: Treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa (HS), Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis, uveitis and paediatric uveitis

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.2. Bevacizumab - EMEA/H/C/005640

Scope: Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and metastatic or recurrent non-small cell lung cancer, advanced and/or metastatic renal cell cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer and persistent, recurrent, or metastatic carcinoma of the cervix. First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First line treatment of patients with advanced and/or metastatic renal cell cancer

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.3. Estetrol, drospirenone - EMEA/H/C/005336

Scope: Oral contraception

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.1.4. Estetrol, drospirenone - EMEA/H/C/005382

Scope: Oral contraception

Action: For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP
5.1.5. **Lisocabtagene maraleucel - EMEA/H/C/004731, Orphan**

Applicant: Celgene Europe BV, ATMP\(^5\)

Scope (accelerated assessment): Treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CAT and CHMP

5.1.6. **Risdiplam - EMEA/H/C/005145, Orphan**

Applicant: Roche Registration GmbH

Scope (accelerated assessment): Treatment of spinal muscular atrophy (SMA)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.2. **Medicines in the post-authorisation phase – PRAC-led procedures**

5.2.1. **Agomelatine - THYMANAX (CAP) - EMEA/H/C/000916/WS1849/0045; VALDOXAN (CAP) - EMEA/H/C/000915/WS1849/0047**

Applicant(s): Les Laboratoires Servier (Valdoxan), Servier (Ireland) Industries Ltd. (Thymanax)

PRAC Rapporteur: Pernille Harg

Scope: Submission of an updated RMP (version 23.1) in order to revise the list of safety concerns, important identified and potential risks in line with revision 2 of GVP module V on ‘Risk management systems’. In addition, the completed studies have been deleted and, as agreed in the conclusions of LEG 031 adopted in January 2019, the frequency of the educational material distribution is updated to once yearly

**Action:** For adoption of PRAC Assessment Report

5.2.2. **Histamine dihydrochloride - CEPLENE (CAP) - EMEA/H/C/000796/II/0040**

Applicant: Noventia Pharma S.r.l.

PRAC Rapporteur: Rhea Fitzgerald

Scope: Submission of an updated RMP (version 8.1) in order to include information about the termination/finalisation of: 1) non-interventional study Ceplene-3290 (listed as a category 3 study in the RMP); an open study designed to gain further knowledge on Ceplene (histamine dihydrochloride) under day to day conditions with special emphasis on tolerability, practicability, usage, and measurable minimal residual disease and course of blast cells and; 2) post-authorisation efficacy study (PAES) Ceplene cohort study 3306: an international, multicentre, observational, non-interventional, registry-based cohort study aiming to describe and evaluate minimal residual disease (MRD) at baseline and follow-up for the assessment of the anti-leukaemic activity of Ceplene (histamine dihydrochloride)/interleukin-2 (IL-2) as remission maintenance therapy in adult patients with acute myeloid leukaemia (AML) in first complete remission (CR1) compared to matched control patients who did not receive Ceplene

\(^5\) Advanced therapy medicinal product
(histamine dihydrochloride)/IL-2. In addition, the RMP is brought in line with revision 2.0.1 of the guidance on the format of RMP in the EU (template). As a consequence, the list of safety concerns is amended in particular ‘drug effect decreased as a consequence of drug interaction’ is added as a new important potential risk

**Action:** For adoption of PRAC Assessment Report

### 5.2.3. Iloprost - VENTAVIS (CAP) - EMEA/H/C/000474/II/0066

Applicant: Bayer AG

PRAC Rapporteur: Adrien Inoubli

Scope: Submission of an updated RMP (version 8.0) to introduce respiratory tract infection as an important potential risk as requested in the conclusions of the periodic safety update report single assessment (PSUSA) procedure (PSUSA/00001724/201709) adopted in May 2018. In addition the MAH took the opportunity to update the RMP in line with revision 2 of GVP module V on ‘Risk management systems’

**Action:** For adoption of PRAC Assessment Report

### 5.2.4. Mannitol - BRONCHITOL (CAP) - EMEA/H/C/001252/II/0042, Orphan

Applicant: Pharmaxis Europe Limited

PRAC Rapporteur: Adrien Inoubli

Scope: Submission of an updated RMP (version 9.0) brought in line with revision 2.0.1 of the guidance on the format of RMP in the EU (template). The MAH took the opportunity to review the safety information and proposed to reclassify ‘cough’ from an important potential risk to an important identified risk; to remove the important identified risks of bronchospasm during and after the initiation dose assessment’ and ‘bronchospasm during long term use’; to remove the important potential risk of ‘cough-related sequelae’, ‘off label use in non-cystic fibrosis (CF) bronchiectasis’, ‘off label use in paediatric/adolescent CF patients (aged 6-17 years)’, ‘administration of Bronchitol via the wrong inhaler device’ and ‘starting Bronchitol treatment without completing the full Bronchitol initiation dose assessment (BIDA) dose’; to remove the missing information of ‘patients requiring home oxygen or needing assisted ventilation’, ‘children <6 years of age’, ‘pregnancy and lactation’, ‘risks associated with long-term use’ from the list of safety concerns; to add ‘increased risk of respiratory or systemic infection’ as an important potential risk replacing ‘pulmonary abscess on continued use’, ‘septicaemia on continued use’, ‘increased risk of bacteria sputum identified or infections with extended use of Bronchitol’ and ‘microbial infection via a contaminated inhaler device’ previously classified as important potential risks. In addition, the pharmacovigilance plan is updated with completed studies. Finally, the RMP is updated as requested in the conclusions of the periodic safety update report single assessment (PSUSA) procedure (PSUSA/00009226/201904) adopted at the November 2019 PRAC meeting

**Action:** For adoption of PRAC Assessment Report

### 5.2.5. Pramipexole - MIRAPEXIN (CAP) - EMEA/H/C/000134/WS1897/0096; SIFROL (CAP) - EMEA/H/C/000133/WS1897/0087

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Anette Kirstine Stark
Scope: Submission of an updated RMP (version 12.0) as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00002491/201904) adopted in December 2019 in order to remove cardiac failure from the list of important identified risks and to amend the information on dopamine agonist withdrawal syndrome (DAWS) as an important identified risk

**Action:** For adoption of PRAC Assessment Report

### 5.2.6. Tacrolimus - ADVAGRAF (CAP) - EMEA/H/C/000712/WS1805/0057; MODIGRAF (CAP) - EMEA/H/C/000954/WS1805/0035; NAP

**Applicant:** Astellas Pharma Europe B.V.

**PRAC Rapporteur:** Ronan Grimes

Scope: Submission of an updated RMP (version 3) in order to add a non-interventional study related to the safety concerns of use during pregnancy and use during lactation. The MAH took the opportunity to combine the two important potential risks of 'exchangeability between the granule and capsule formulations of tacrolimus' for Modigraf (tacrolimus) and 'if administered accidentally either arterially or perivascularly, the reconstituted solution may cause irritation at the injection site' for Prograf (tacrolimus) concentrate for solution for infusion into the important identified risk of 'medication errors'. Finally, the RMP is updated in line with revision 2.0.1 of the guidance on the format of RMP in the EU (template)

**Action:** For adoption of PRAC Assessment Report

### 5.2.7. Tolvaptan - JINARC (CAP) - EMEA/H/C/002788/II/0029

**Applicant:** Otsuka Pharmaceutical Netherlands B.V.

**PRAC Rapporteur:** Amelia Cupelli

Scope: Submission of an updated RMP (version 14.4) to include dehydration and the pregnancy prevention programme as additional risk minimisation measures (aRMM) in order to align the RMP with Annex II-D on 'Conditions or restrictions with regard to the safe and effective use of the medicinal product'

**Action:** For adoption of PRAC Assessment Report

### 5.2.8. Trabectedin - YONDELIS (CAP) - EMEA/H/C/000773/II/0061

**Applicant:** Pharma Mar, S.A.

**PRAC Rapporteur:** Hans Christian Siersted

Scope: Submission of an updated RMP (version 9.0) in order to reflect new available data from completed studies, removal of safety concerns and removal of a target follow-up questionnaire. The RMP is also brought in line with revision 2.0.1 of the guidance on the format of RMP in the EU (template)

**Action:** For adoption of PRAC Assessment Report
5.2.9. **Umeclidinium bromide - INCRUSE ELLIPTA (CAP) - EMEA/H/C/002809/WS1589/0029; ROLUFTA ELLIPTA (CAP) - EMEA/H/C/004654/WS1589/0014**

Applicant: GlaxoSmithKline (Ireland) Limited (Incruse Ellipta), GlaxoSmithKline Trading Services Limited (Rolufta Ellipta)

PRAC Rapporteur: Ilaria Baldelli

Scope: Submission of an updated RMP (version 7.1) following completion of study WWE117397 (listed as a category 3 in the RMP): a post-authorisation safety electronic medical records database retrospective cohort study of new users of inhaled umclidinium/vilanterol (UMEC/VI) or new users of inhaled umclidinium (UMEC) in the primary care setting. In addition, updates are reflected in the RMP with regard to study 201038 (listed as a category 1 in the RMP/Annex II): a post authorisation safety observational cohort study to quantify the incidence of selected cardiovascular and cerebrovascular events in chronic obstructive pulmonary disease (COPD) patients using inhaled UMEC/VI combination or inhaled UMEC versus tiotropium, as requested in the conclusions of procedure PSA/S/0032.3 adopted in November 2019. These include updates of the primary and secondary objectives to include the composite endpoint and the sample size for the study. Finally, the RMP is brought in line with revision 2 of GVP module V on ‘Risk management systems’

**Action:** For adoption of PRAC Assessment Report

5.3. **Medicines in the post-authorisation phase – CHMP-led procedures**

5.3.1. **Avatrombopag - DOPELET (CAP) - EMEA/H/C/004722/II/0004/G**

Applicant: Swedish Orphan Biovitrum AB (publ)

PRAC Rapporteur: Eva Segovia

Scope: Grouped variations consisting of: 1) extension of indication to include the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, section 5.3 of the SmPC is updated with data from juvenile toxicity studies; 2) addition of a pack size with subsequent updates of sections 6.5 and 8 of the SmPC. The package leaflet, labelling and the RMP (version 2.1) are updated in accordance. Furthermore, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.1)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.2. **Beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium - TRIMBOW (CAP) - EMEA/H/C/004257/X/0008/G**

Applicant: Chiesi Farmaceutici S.p.A.

PRAC Rapporteur: Jan Neuhauser

Scope: Grouped application consisting of: 1) extension application to introduce a new strength; 2) update of sections 4.1, 4.2, 4.4, 5.1 and 5.2 of the SmPC to extend the indication to the maintenance treatment in adult patients with asthma who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or who are already treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist plus a
long-acting muscarinic antagonist. The RMP (version 6.1) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.3. Belatacept - NULOJIX (CAP) - EMEA/H/C/002098/II/0070

**Applicant:** Bristol-Myers Squibb Pharma EEIG  
**PRAC Rapporteur:** Ulla Wändel Liminga  
**Scope:** Extension of indication to include the use of belatacept in conversion from a calcineurin inhibitor-based regimen to a belatacept-based regimen post transplantation. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 18.0) are updated in accordance. Furthermore, the MAH took the opportunity to bring the product information in line with the latest quality review of documents (QRD) template (version 10.1) and to update it with regard to sodium content in line with the Annex to the European Commission (EC) guideline on ‘excipients in the labelling and package leaflet of medicinal products for human use’  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.4. Carfilzomib - KYPROLIS (CAP) - EMEA/H/C/003790/II/0045, Orphan

**Applicant:** Amgen Europe B.V.  
**PRAC Rapporteur:** Nikica Mirošević Skvrce  
**Scope:** Extension of existing indication to include combination of Kyprolis (carfilzomib) with daratumumab and dexamethasone. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.5. Fluticasone furoate, umeclidinium, vilanterol - ELEBRATO ELLIPTA (CAP) - EMEA/H/C/004781/X/0014/G

**Applicant:** GlaxoSmithKline Trading Services Limited  
**PRAC Rapporteur:** Annika Folin  
**Scope:** Grouped application consisting of: 1) extension application to introduce a new strength; 2) extension of indication to add maintenance treatment in adult patients with asthma. As a consequence, sections 2, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet and the RMP (version 2.2) are updated in accordance  
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

---

### 5.3.6. Fluticasone furoate, umeclidinium, vilanterol - TEMYBRIC ELLIPTA (CAP) - EMEA/H/C/005254/X/0004/G

**Applicant:** GlaxoSmithKline Trading Services Limited  
**PRAC Rapporteur:** Annika Folin  
**Scope:** Grouped application consisting of: 1) extension application to introduce a new strength; 2) extension of indication to add maintenance treatment in adult patients with asthma. As a consequence, sections 2, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The
package leaflet and the RMP (version 2.2) are updated in accordance.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.7. Fluticasone furoate, umeclidinium, vilanterol - TRELEGY ELLIPTA (CAP) - EMEA/H/C/004363/X/0012/G

Applicant: GlaxoSmithKline Trading Services Limited

PRAC Rapporteur: Annika Folin

Scope: Grouped application consisting of: 1) extension application to introduce a new strength; 2) extension of indication to add maintenance treatment in adult patients with asthma. As a consequence, sections 2, 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet and the RMP (version 2.2) are updated in accordance.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.8. Follitropin delta - REKOVELLE (CAP) - EMEA/H/C/003994/II/0022

Applicant: Ferring Pharmaceuticals A/S

PRAC Rapporteur: Menno van der Elst

Scope: Update of section 4.2 of the SmPC in order to introduce a new anti-Müllerian hormone (AMH) assay to determine the dose of follitropin delta, following an agreed recommendation. The RMP (version 5.0) is updated accordingly and in line with revision 2 of GVP module V on 'Risk management systems'. The MAH took the opportunity to amend section 4.4 of the SmPC to introduce traceability information. Finally, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.1).

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.9. Ipilimumab - YERVOY (CAP) - EMEA/H/C/002213/WS1840/0084; nivolumab - OPDIVO (CAP) - EMEA/H/C/003985/WS1840/0089

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Extension of indication to include treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) for combination treatment with Opdivo (nivolumab) and Yervoy (ipilimumab). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet and the RMPs (Opdivo version 18.0, Yervoy version 29.0) are updated in accordance.

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.10. Lacosamide - LACOSAMIDE ACCORD (CAP) - EMEA/H/C/004443/X/0007

Applicant: Accord Healthcare S.L.U.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Extension application to introduce a new pharmaceutical form (solution for infusion), a new strength and a new route of administration (intravenous use). The RMP (version 1.0) is updated accordingly.
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.11. **Lipegfilgrastim - LONQUEX (CAP) - EMEA/H/C/002556/II/0058/G**

Applicant: Teva B.V.

PRAC Rapporteur: Kirsti Villikka

Scope: Grouped variations consisting of an extension of indication to include treatment of the paediatric population and introduction of an age appropriate presentation in vials. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet and the RMP (version 12.0) are updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the package leaflet. Furthermore, the product information is brought in line with the latest quality review of documents (QRD) template (version 10.1)

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.12. **Natalizumab - TYSABRI (CAP) - EMEA/H/C/000603/X/0116**

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Extension application to introduce a new pharmaceutical form associated with a new strength and a new route of administration. The RMP (version 26.1) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.13. **Nintedanib - VARGATEF (CAP) - EMEA/H/C/002569/II/0035/G**

Applicant: Boehringer Ingelheim International GmbH

PRAC Rapporteur: Agni Kapou

Scope: Grouped variations consisting of: 1) update of sections 4.5, 4.6 and 5.2 of the SmPC to reflect the results of study 1199-0340 conducted in female patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) to investigate a potential interaction between nintedanib and a combined oral contraceptive (COC) containing ethynilestradiol/levonorgestrel; 2) update of sections 4.3 and 4.6 of the SmPC to introduce a new contraindication of pregnancy. This follows the update for Ofev (nintedanib) on SSc-ILD introduced in the context of variation II/0026 finalised in February 2020 and as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00010318/201910) adopted in May 2020. The package leaflet and the RMP (version 7.0) are updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

5.3.14. **Ocrelizumab - OCREVUS (CAP) - EMEA/H/C/004043/II/0021**

Applicant: Roche Registration GmbH

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Update of section 4.4 in order to include the term 'anaphylaxis' among the possible symptoms of infusion-related reactions (IRRs), following an analysis of cases retrieved by
anaphylactic reaction MedDRA® narrow standardised MedDRA queries (SMQ). The MAH took the opportunity to update Annex II-C on 'Other conditions and requirements of the marketing authorisation' and Annex II-D on 'Conditions or restrictions with regard to the safe and effective use of the medicinal product’ in line with the latest quality review of documents (QRD) template (version 10.1). The RMP (version 6.0) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.15. Pegvisomant - SOMAVERT (CAP) - EMEA/H/C/000409/II/0098/G

**Applicant:** Pfizer Europe MA EEIG  
**PRAC Rapporteur:** Adrien Inoubli  
**Scope:** Grouped variations consisting of: 1) update of section 4.4 of the SmPC to remove the warning on growth hormone secreting tumours, consequential to the removal of pituitary tumour growth as a potential risk from the RMP. The package leaflet is updated accordingly; 2) update of the RMP (version 2.0) to reflect the evaluation of the final results of study A6291010 (ACROSTUDY) (listed as a category 3 study in the RMP): an open-label, global, multicentre, non-interventional PASS performed to monitor the long-term safety and outcomes of pegvisomant treatment in clinical practice as per the conclusions of variation II/0089 adopted in July 2019. The RMP is also brought in line with revision 2 of GVP module V on ‘Risk management systems’

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.16. Rituximab - BLITZIMA (CAP) - EMEA/H/C/004723/WS1893/0034; RITEMVIA (CAP) - EMEA/H/C/004725/WS1893/0034; TRUXIMA (CAP) - EMEA/H/C/004112/WS1893/0037

**Applicant:** Celltrion Healthcare Hungary Kft.  
**PRAC Rapporteur:** Hans Christian Siersted  
**Scope:** Submission of the final clinical study report (CSR) for study CT-P10 3.4: a phase 3, randomised, parallel-group, active-controlled, double-blind study to compare efficacy and safety between CT-P10 (Blitzima/Ritemvia/Truxima (biosimilar rituximab)) and Rituxan/Mabthera (rituximab) in patients with low tumour burden follicular lymphoma (LTBFL). The RMP (version 10.1) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.17. Rivaroxaban - XARELTO (CAP) - EMEA/H/C/000944/X/0074/G

**Applicant:** Bayer AG  
**PRAC Rapporteur:** Ulla Wändel Liminga  
**Scope:** Grouped applications consisting of: 1) extension application to introduce a new pharmaceutical form, granules for oral suspension; 2) extension of indication to include treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children and adolescents aged less than 18 years following initiation of standard anticoagulation treatment for Xarelto (rivaroxaban) 15 mg and 20 mg tablets. As a consequence, sections 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPC are

---

6 Medical Dictionary for Regulatory Activities
updated. The package leaflet and the RMP (version 12.1) are updated accordingly. In addition, sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated for all other dose strengths (2.5/10 mg and 15/20 mg initiation packs). Furthermore, the MAH took the opportunity to update the product information with regards to sodium content in line with the Annex to the European Commission (EC) guideline on ‘excipients in the labelling and package leaflet of medicinal products for human use’

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.18. Rucaparib - RUBRACA (CAP) - EMEA/H/C/004272/II/0020

**Applicant:** Clovis Oncology Ireland Limited  
**PRAC Rapporteur:** Annika Folin  
**Scope:** Update of sections 4.2 and 5.2 of the SmPC in order to update the information on the use of rucaparib in patients with hepatic impairment based on final results from part I of study CO-338-078 (listed as a category 3 study in the RMP): a phase 1, open-label, parallel group study to determine the pharmacokinetics, safety and tolerability of rucaparib in patients with an advanced solid tumour and either moderate hepatic impairment or normal hepatic function. The package leaflet and the RMP (version 4.0) are updated accordingly. The MAH took the opportunity to introduce minor corrections in the SmPC, to update the list of local representatives in the package leaflet, and to bring the product information in line with the latest quality review of documents (QRD) template (version 10.1), and in line with the European Commission (EC) guideline on ‘excipients in the labelling and package leaflet of medicinal products for human use’

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.19. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/WS1830/0032; NEPARVIS (CAP) - EMEA/H/C/004343/WS1830/0029

**Applicant:** Novartis Europharm Limited  
**PRAC Rapporteur:** Anette Kirstine Stark  
**Scope:** Submission of the final report from study CLCZ696D2301 (PARAGON HF) (listed as a category 3 study in the RMP): a multicentre, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 (sacubitril/valsartan) compared to valsartan, on morbidity and mortality in heart failure patients (NYHA\(^7\) class II-IV) with preserved ejection fraction to evaluate cognitive function. The RMP (version 2.0) is updated accordingly

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.20. Sodium phenylbutyrate - PHEBURANE (CAP) - EMEA/H/C/002500/X/0026

**Applicant:** Eurocept International B.V.  
**PRAC Rapporteur:** Rhea Fitzgerald  
**Scope:** Extension application to introduce a new pharmaceutical form associated with a new strength. The RMP (version 0.1) is updated in accordance

---

\(^7\) New York Heart Association
**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.21. Sodium phenylbutyrate - PHEBURANE (CAP) - EMEA/H/C/002500/X/0028

**Applicant:** Eurocept International B.V.

**PRAC Rapporteur:** Rhea Fitzgerald

**Scope:** Extension application to introduce a new pharmaceutical form associated with a new strength. The RMP (version 0.1) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 5.3.22. Stiripentol - DIACOMIT (CAP) - EMEA/H/C/000664/X/0032

**Applicant:** Biocodex

**PRAC Rapporteur:** Maia Uusküla

**Scope:** Extension application to add a new strength. The RMP (version 2.0) is updated in accordance

**Action:** For adoption of PRAC RMP AR, PRAC RMP assessment overview and advice to CHMP

### 6. Periodic safety update reports (PSURs)

#### 6.1. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) only

##### 6.1.1. Abemaciclib - VERZENIOS (CAP) - PSUSA/00010724/202003

**Applicant:** Eli Lilly Nederland B.V.

**PRAC Rapporteur:** Marcia Sofia Sanches de Castro Lopes Silva

**Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

##### 6.1.2. Alogliptin - VIPIDIA (CAP); alogliptin, metformin - VIPDOMET (CAP); alogliptin, pioglitazone - INCRESYNC (CAP) - PSUSA/00010061/202004

**Applicant(s):** Takeda Pharma A/S

**PRAC Rapporteur:** Menno van der Elst

**Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

##### 6.1.3. Avelumab - BAVENCIO (CAP) - PSUSA/00010635/202003

**Applicant:** Merck Europe B.V.

**PRAC Rapporteur:** Hans Christian Siersted

**Scope:** Evaluation of a PSUSA procedure
<table>
<thead>
<tr>
<th>Action: For adoption of recommendation to CHMP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>6.1.4. Brolucizumab - BEOVU (CAP) - PSUSA/00010829/202004</strong></td>
</tr>
<tr>
<td>Applicant: Novartis Europharm Limited</td>
</tr>
<tr>
<td>PRAC Rapporteur: Brigitte Keller-Stanislawski</td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Action: For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td><strong>6.1.5. Canagliflozin - INVOKANA (CAP); canagliflozin, metformin - VOKANAMET (CAP) - PSUSA/00010077/202003</strong></td>
</tr>
<tr>
<td>Applicant(s): Janssen-Cilag International NV</td>
</tr>
<tr>
<td>PRAC Rapporteur: Martin Huber</td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Action: For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td><strong>6.1.6. Cemiplimab - LIBTAYO (CAP) - PSUSA/00010780/202003</strong></td>
</tr>
<tr>
<td>Applicant: Regeneron Ireland Designated Activity Company (DAC)</td>
</tr>
<tr>
<td>PRAC Rapporteur: Menno van der Elst</td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Action: For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td><strong>6.1.7. Certolizumab - CIMZIA (CAP) - PSUSA/00000624/202003</strong></td>
</tr>
<tr>
<td>Applicant: UCB Pharma S.A.</td>
</tr>
<tr>
<td>PRAC Rapporteur: Ulla Wändel Liminga</td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Action: For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td><strong>6.1.8. Dacomitinib - VIZIMPRO (CAP) - PSUSA/00010757/202003</strong></td>
</tr>
<tr>
<td>Applicant: Pfizer Europe MA EEIG</td>
</tr>
<tr>
<td>PRAC Rapporteur: Menno van der Elst</td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Action: For adoption of recommendation to CHMP</td>
</tr>
<tr>
<td><strong>6.1.9. Dapagliflozin - EDISTRIDE (CAP); FORXIGA (CAP) - PSUSA/00010029/202004</strong></td>
</tr>
<tr>
<td>Applicant(s): AstraZeneca AB</td>
</tr>
<tr>
<td>PRAC Rapporteur: Annika Folin</td>
</tr>
<tr>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
</tbody>
</table>
**Action:** For adoption of recommendation to CHMP

### 6.1.10. Darvadstrocel - ALOFISEL (CAP) - PSUSA/00010676/202003

- **Applicant:** Takeda Pharma A/S, ATMP
- **PRAC Rapporteur:** Brigitte Keller-Stanislawski
- **Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CAT and CHMP

### 6.1.11. Dupilumab - DUPIXENT (CAP) - PSUSA/00010645/202003

- **Applicant:** Sanofi-aventis groupe
- **PRAC Rapporteur:** Kimmo Jaakkola
- **Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.12. Emtricitabine - EMTRIVA (CAP) - PSUSA/00001209/202004

- **Applicant:** Gilead Sciences Ireland UC
- **PRAC Rapporteur:** Ana Sofia Diniz Martins
- **Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.13. Emtricitabine, tenofovir alafenamide - DESCOVY (CAP) - PSUSA/00010515/202004

- **Applicant:** Gilead Sciences Ireland UC
- **PRAC Rapporteur:** Ana Sofia Diniz Martins
- **Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.14. Emtricitabine, tenofovir disoproxil - TRUVADA (CAP) - PSUSA/00001210/202004

- **Applicant:** Gilead Sciences Ireland UC
- **PRAC Rapporteur:** Ana Sofia Diniz Martins
- **Scope:** Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.15. Exenatide - BYDUREON (CAP); BYETTA (CAP) - PSUSA/00009147/202003

- **Applicant(s):** AstraZeneca AB
- **PRAC Rapporteur:** Annika Folin
- **Scope:** Evaluation of a PSUSA procedure

---

8 Advanced therapy medicinal product
Action: For adoption of recommendation to CHMP

6.1.16. Fostamatinib - TAVLESSE (CAP) - PSUSA/00010819/202004

Applicant: Instituto Grifols, S.A.
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.17. Galcanezumab - EMGALITY (CAP) - PSUSA/00010733/202003

Applicant: Eli Lilly Nederland B.V.
PRAC Rapporteur: Kirsti Villikka
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.18. Gilteritinib - XOSPATA (CAP) - PSUSA/00010832/202003

Applicant: Astellas Pharma Europe B.V.
PRAC Rapporteur: Martin Huber
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.19. Herpes zoster vaccine (recombinant, adjuvanted) - SHINGRIX (CAP) - PSUSA/00010678/202004

Applicant: GlaxoSmithkline Biologicals SA
PRAC Rapporteur: Sonja Hrabcik
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.20. Histamine9 - CEPLENE (CAP) - PSUSA/00001610/202004

Applicant: Noventa Pharma S.r.l.
PRAC Rapporteur: Rhea Fitzgerald
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CHMP

6.1.21. Insulin glulisine - APIDRA (CAP) - PSUSA/00001752/202004

Applicant: Sanofi-Aventis Deutschland GmbH
PRAC Rapporteur: Hans Christian Siersted

9 Indicated for the treatment of acute myeloid leukaemia (AML)
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.22. Ipilimumab - YERVOY (CAP) - PSUSA/00009200/202003

Applicant: Bristol-Myers Squibb Pharma EEIG

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.23. Ixekizumab - TALTZ (CAP) - PSUSA/00010493/202003

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.24. Lorlatinib - LORVIQUA (CAP) - PSUSA/00010760/202003

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.25. Lusutrombopag - MULPLEO (CAP) - PSUSA/00010755/202003

Applicant: Shionogi B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.26. Meningococcal group A, C, W-135, Y conjugate vaccine (conjugated to Corynebacterium diphtheriae CRM197 protein) - MENVEO (CAP) - PSUSA/00001969/202003

Applicant: GSK Vaccines S.r.l

PRAC Rapporteur: Menno van der Elst

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.1.27. Mogamulizumab - POTELIGEO (CAP) - PSUSA/00010741/202003

Applicant: Kyowa Kirin Holdings B.V.
PRAC Rapporteur: Hans Christian Siersted
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.28. Naldemedine - RIZMOIC (CAP) - PSUSA/00010753/202003

Applicant: Shionogi B.V.
PRAC Rapporteur: Rhea Fitzgerald
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.29. Nintedanib\(^{10}\) - OFEV (CAP) - PSUSA/00010319/202004

Applicant: Boehringer Ingelheim International GmbH
PRAC Rapporteur: Nikica Mirošević Skvrce
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.30. Niraparib - ZEJULA (CAP) - PSUSA/00010655/202003

Applicant: GlaxoSmithKline (Ireland) Limited
PRAC Rapporteur: Jan Neuhauser
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.31. Ocrelizumab - OCREVUS (CAP) - PSUSA/00010662/202003

Applicant: Roche Registration GmbH
PRAC Rapporteur: Brigitte Keller-Stanislawski
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.32. Risankizumab - SKYRIZI (CAP) - PSUSA/00010765/202003

Applicant: AbbVie Deutschland GmbH & Co. KG
PRAC Rapporteur: Liana Gross-Martirosyan
Scope: Evaluation of a PSUSA procedure
**Action:** For adoption of recommendation to CHMP

### 6.1.33. Siponimod - MAYZENT (CAP) - PSUSA/00010818/202003 (with RMP)

Applicant: Novartis Europharm Limited

\(^{10}\) Respiratory indication(s) only
<table>
<thead>
<tr>
<th>Action</th>
<th>6.1.34. Sodium zirconium cyclosilicate - LOKELMA (CAP) - PSUSA/00010675/202003</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAC Rapporteur: Maria del Pilar Rayon</td>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Applicant: AstraZeneca AB</td>
<td></td>
</tr>
<tr>
<td>PRAC Rapporteur: Kirsti Villikka</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Action</th>
<th>6.1.35. Talazoparib - TALZENNA (CAP) - PSUSA/00010781/202004</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAC Rapporteur: Kirsti Villikka</td>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Applicant: Pfizer Europe MA EEIG</td>
<td></td>
</tr>
<tr>
<td>PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Action</th>
<th>6.1.36. Trifluridine, tipiracil - LONSURF (CAP) - PSUSA/00010517/202003</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAC Rapporteur: Annika Folin</td>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Applicant: Les Laboratoires Servier</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Action</th>
<th>6.1.37. Vandetanib - CAPRELSA (CAP) - PSUSA/00009327/202004</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAC Rapporteur: Tiphaine Vaillant</td>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Applicant: Genzyme Europe BV</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Action</th>
<th>6.1.38. Velmanase alfa - LAMZEDE (CAP) - PSUSA/00010677/202003</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAC Rapporteur: Jan Neuhauser</td>
<td>Scope: Evaluation of a PSUSA procedure</td>
</tr>
<tr>
<td>Applicant: Chiesi Farmaceutici S.p.A.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Action</th>
<th>6.1.39. Yttrium (90Y) chloride - YTRACIS (CAP); YTTRIGA (CAP) - PSUSA/00003137/202003</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRAC Rapporteur: Menno van der Elst</td>
<td>Applicant(s): Cis Bio International (Ytracis), Eckert &amp; Ziegler Radiopharma GmbH (Yttriga)</td>
</tr>
</tbody>
</table>
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.2. PSUR single assessment (PSUSA) procedures including centrally authorised products (CAPs) and nationally authorised products (NAPs)

#### 6.2.1. Enoxaparin - INHIXA (CAP); NAP - PSUSA/00010833/202004

Applicant(s): Techdow Pharma Netherlands B.V. (Inhixa), various
PRAC Rapporteur: Menno van der Elst
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.2.2. Tenofovir disoproxil - TENOFOVIR DISOPROXIL MYLAN (CAP); TENOVOIR DISOPROXIL ZENTIVA (CAP); VIREAD (CAP); NAP - PSUSA/00002892/202003

Applicant(s): Gilead Sciences Ireland UC (Viread), Mylan S.A.S (Tenofovir disoproxil Mylan), Zentiva k.s. (Tenofovir disoproxil Zentiva), various
PRAC Rapporteur: Adrien Inoubli
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

#### 6.2.3. Zonisamide - ZONEGRAN (CAP); NAP - PSUSA/00003152/202003

Applicant(s): Eisai GmbH, various
PRAC Rapporteur: Ronan Grimes
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CHMP

### 6.3. PSUR single assessment (PSUSA) procedures including nationally authorised products (NAPs) only

#### 6.3.1. Ascorbic acid, paracetamol, pheniramine maleate (NAP) - PSUSA/00002368/202003

Applicant(s): various
PRAC Lead: Maia Uusküla
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

#### 6.3.2. Ethosuximide (NAP) - PSUSA/00001316/202003

Applicant(s): various
PRAC Lead: Anette Kirstine Stark
Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.3. Fluconazole (NAP) - PSUSA/00001404/202003

Applicant(s): various

PRAC Lead: Anette Kirstine Stark

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.4. Flucloxacillin (NAP) - PSUSA/00001402/202003

Applicant(s): various

PRAC Lead: Ana Sofia Diniz Martins

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.5. Galantamine (NAP) - PSUSA/00001512/202003

Applicant(s): various

PRAC Lead: Ulla Wändel Liminga

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.6. Hydroxyethyl starch (HES) (NAP) - PSUSA/00001694/202003

Applicant(s): various

PRAC Lead: Martin Huber

Scope: Evaluation of a PSUSA procedure

**Action:** For discussion

### 6.3.7. Lanthanum (NAP) - PSUSA/00003175/202003

Applicant(s): various

PRAC Lead: Roxana Stefania Stroe

Scope: Evaluation of a PSUSA procedure

**Action:** For adoption of recommendation to CMDh

### 6.3.8. Metamizole (NAP) - PSUSA/00001997/202003

Applicant(s): various

PRAC Lead: Melinda Palfi

Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.3.9. Trandolapril, verapamil (NAP) - PSUSA/00003005/202003

Applicant(s): various
PRAC Lead: Menno van der Elst
Scope: Evaluation of a PSUSA procedure
Action: For adoption of recommendation to CMDh

6.4. Follow-up to PSUR/PSUSA procedures

6.4.1. Lenalidomide - REVLIMID (CAP) - EMEA/H/C/000717/LEG 050

Applicant: Celgene Europe BV
PRAC Rapporteur: Tiphaine Vaillant
Scope: Detailed review of cases of B-cell acute lymphoblastic leukaemia as requested in the conclusions of the PSUR single assessment (PSUSA) procedure (PSUSA/00001838/201912) adopted in July 2020
Action: For adoption of advice to CHMP

6.5. Variation procedure(s) resulting from PSUSA evaluation

6.5.1. Ixazomib - NINLARO (CAP) - EMEA/H/C/003844/II/0022, Orphan

Applicant: Takeda Pharma A/S
PRAC Rapporteur: Annika Folin
Scope: Update of section 4.8 to add acute febrile neutrophilic dermatosis (Sweet’s syndrome), Stevens-Johnson syndrome, transverse myelitis, posterior reversible encephalopathy syndrome, tumour lysis syndrome as requested in the conclusions of the latest periodic safety update report single assessment (PSUSA) procedure (PSUSA/00010535/201911) adopted in June 2020. The package leaflet is updated accordingly
Action: For adoption of PRAC Assessment Report

6.6. Expedited summary safety reviews11

6.6.1. Remdesivir - VEKLURY (CAP) - EMEA/H/C/005622/MEA 017.3

Applicant: Gilead Sciences Ireland UC
PRAC Rapporteur: Eva Jirsová
Scope: Sixth expedited monthly summary safety report for remdesivir for October 2020 including spontaneously reported data and data from compassionate use and expanded access programmes for the duration of the coronavirus disease (COVID-19) pandemic

11 Submission of expedited summary safety reports for review in addition to the requirements for submission of PSUR(s) falling within the pandemic period and requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC
7. Post-authorisation safety studies (PASS)

7.1. Protocols of PASS imposed in the marketing authorisation(s)\textsuperscript{12}

7.1.1. Betibeglogene autotemcel – ZYNTEGLO (CAP) - EMEA/H/C/PSA/S/0059

- **Applicant:** Bluebird bio (Netherlands) B.V., ATMP\textsuperscript{13}
- **PRAC Rapporteur:** Brigitte Keller-Stanislawski
- **Scope:** Protocol for a non-interventional PASS to collect longitudinal data on clinical outcomes of patients with transfusion-dependent β-thalassaemia (TDT) who have received treatment with Zynteglo (betibeglogene autotemcel) in the post-marketing setting
- **Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.2. Eliglustat – CERDELGA (CAP) - EMEA/H/C/PSA/S/0054.1

- **Applicant:** Genzyme Europe BV
- **PRAC Rapporteur:** Eva Segovia
- **Scope:** MAH’s response to PSA/S/0054 [substantial amendment to a protocol previously agreed in December 2018 (PSA/S/0035) for a prospective multicentre observational post-authorisation safety sub-registry to characterise the long-term safety profile of commercial use of Cerdelga (eliglustat) in adult patients with Gaucher disease] as per the request for supplementary information (RSI) adopted in June 2020
- **Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.3. Methylphenidate hydrochloride (NAP) - EMEA/H/N/PSP/S/0064.5

- **Applicant:** Medice Arzneimittel Pütter GmbH & Co. KG (Medikinet)
- **PRAC Rapporteur:** Martin Huber
- **Scope:** MAH’s response to PSP/S/0064.4 [protocol for a multicentre, observational, prospective PASS to evaluate the safety concerns of long-term cardiovascular and psychiatric risks within the adult attention deficit/hyperactivity disorder (ADHD) population taking Medikinet Retard (methylphenidate hydrochloride) according to normal standard clinical practice] as per the request for supplementary information (RSI) adopted in June 2020
- **Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

7.1.4. Parathyroid hormone – NATPAR (CAP) - EMEA/H/C/PSA/S/0053.1

- **Applicant:** Shire Pharmaceuticals Ireland
- **PRAC Rapporteur:** Rhea Fitzgerald
- **Scope:** MAH’s response to PSA/S/0053 [substantial amendment to a protocol previously agreed in March 2018 (PSA/S/0026) for study PARADIGHM (physicians advancing disease

\textsuperscript{12} In accordance with Article 107n of Directive 2001/83/EC

\textsuperscript{13} Advanced therapy medicinal product
knowledge in hypoparathyroidism): a registry for subjects with chronic hypoparathyroidism to explore physicians advancing disease knowledge in hypoparathyroidism] as per the request for supplementary information (RSI) adopted in June 2020

**Action:** For adoption of PRAC Assessment Report, PRAC outcome letter

### 7.2. Protocols of PASS non-imposed in the marketing authorisation(s)\(^{14}\)

#### 7.2.1. Darbepoetin alfa - ARANESP (CAP) - EMEA/H/C/000332/MEA 092.1

**Applicant:** Amgen Europe B.V.

**PRAC Rapporteur:** Martin Huber

**Scope:** MAH’s response to MEA 092 [protocol for study 20190404: a retrospective cohort study to assess the use of erythropoiesis stimulating agents (ESAs) in subjects receiving myelosuppressive chemotherapy in Europe] as per the request for supplementary information (RSI) adopted in May 2020

**Action:** For adoption of advice to CHMP

#### 7.2.2. Interferon beta-1a - AVONEX (CAP) - EMEA/H/C/000102/MEA 088.1

**Applicant:** Biogen Netherlands B.V.

**PRAC Rapporteur:** Maria del Pilar Rayon

**Scope:** MAH’s response to MEA 088 [protocol for a joint PASS for study 2600153 (INFORM): an observational study regarding interferon beta exposure in the second and third trimesters of pregnancy - a register-based drug utilisation study (DUS) in Finland and Sweden] as per the request for supplementary information (RSI) adopted in April 2020

**Action:** For adoption of advice to CHMP

#### 7.2.3. Interferon beta-1a - REBIF (CAP) - EMEA/H/C/000136/MEA 045.1

**Applicant:** Merck Europe B.V.

**PRAC Rapporteur:** Ulla Wändel Liminga

**Scope:** MAH’s response to MEA 045 [protocol for a joint PASS for study 2600153 (INFORM): an observational study regarding interferon beta exposure in the second and third trimesters of pregnancy - a register-based drug utilisation study (DUS) in Finland and Sweden] as per the request for supplementary information (RSI) adopted in April 2020

**Action:** For adoption of advice to CHMP

#### 7.2.4. Interferon beta-1b - BETAFERON (CAP) - EMEA/H/C/000081/MEA 025.1

**Applicant:** Bayer AG

**PRAC Rapporteur:** Martin Huber

**Scope:** MAH’s response to MEA 025 [protocol for a joint PASS for study 2600153 (INFORM): an observational study regarding interferon beta exposure in the second and third trimesters of pregnancy - a register-based drug utilisation study (DUS) in Finland and Sweden] as per the request for supplementary information (RSI) adopted in April 2020

**Action:** For adoption of advice to CHMP

\(^{14}\) In accordance with Article 107m of Directive 2001/83/EC, supervised by PRAC in accordance with Article 61a (6) of Regulation (EC) No 726/2004
pregnancy - a register-based drug utilisation study (DUS) in Finland and Sweden] as per the request for supplementary information (RSI) adopted in April 2020

**Action:** For adoption of advice to CHMP

### 7.2.5. Interferon beta-1b - EXTAVIA (CAP) - EMEA/H/C/000933/MEA 023.1

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Martin Huber

Scope: MAH’s response to MEA 023 [protocol for a joint PASS for study 2600153 (INFORM): an observational study regarding interferon beta exposure in the second and third trimesters of pregnancy - a register-based drug utilisation study (DUS) in Finland and Sweden] as per the request for supplementary information (RSI) adopted in April 2020

**Action:** For adoption of advice to CHMP

### 7.2.6. Luspatercept - REBLOZYL (CAP) - EMEA/H/C/004444/MEA 004

Applicant: Celgene Europe BV

PRAC Rapporteur: Laurence de Fays

Scope: Amendment to a protocol previously agreed in the framework of the initial marketing authorisation application (MAA) procedure for study ACE-536-LTFU-001: a phase 3b, open label, single-arm rollover study to evaluate long term safety in subjects who have participated in other luspatercept clinical trials in order to amend the iron parameters

**Action:** For adoption of advice to CHMP

### 7.2.7. Peginterferon beta-1a - PLEGRIDY (CAP) - EMEA/H/C/002827/MEA 010.1

Applicant: Biogen Netherlands B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: MAH’s response to MEA 010 [protocol for a joint PASS for study 2600153 (INFORM): an observational study regarding interferon beta exposure in the second and third trimesters of pregnancy - a register-based drug utilisation study (DUS) in Finland and Sweden] as per the request for supplementary information (RSI) adopted in April 2020

**Action:** For adoption of advice to CHMP

### 7.2.8. Semaglutide - OZEMPIC (CAP) - EMEA/H/C/004174/MEA 002.1

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Annika Folin

Scope: Substantial amendment to a protocol previously agreed in September 2018 (MEA 002) for study NN9535-4447: an epidemiological database study to estimate the risk of pancreatic cancer in patients with type 2 diabetes mellitus (T2DM) taking semaglutide - a cohort study based on Nordic registry data [final study report expected 5 years after start of study]

**Action:** For adoption of advice to CHMP
7.2.9.  **Semaglutide - RYBELSUS (CAP) - EMEA/H/C/004953/MEA 002**

Applicant: Novo Nordisk A/S

PRAC Rapporteur: Annika Folin

Scope: Substantial amendment to a protocol previously agreed in September 2018 (Ozempic MEA 002) for study NN9535-4447: an epidemiological database study to estimate the risk of pancreatic cancer in patients with type 2 diabetes mellitus (T2DM) taking semaglutide - a cohort study based on Nordic registry data [final study report expected 5 years after start of study]

**Action:** For adoption of advice to CHMP

7.2.10.  **Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/MEA 015.1**

Applicant: Pfizer Europe MA EEIG

PRAC Rapporteur: Liana Gross-Martirosyan

Scope: MAH’s response to MEA 015 [protocol for study A3921334: a non-interventional PASS to evaluate the effectiveness of additional risk minimisation measures (aRMM) materials for Xeljanz (tofacitinib) in Europe via a survey of healthcare professionals (HCPs), as requested in the conclusions of the referral procedure under Article 20 of Regulation (EC) No 726/2004 (EMEA/H/A-20/1485) finalised in November 2019] as per the request for supplementary information (RSI) adopted in July 2020

**Action:** For adoption of advice to CHMP

7.3.  **Results of PASS imposed in the marketing authorisation(s)**

None

7.4.  **Results of PASS non-imposed in the marketing authorisation(s)**

7.4.1.  **Aclidinium - BRETARIS GENUAIR (CAP) - EMEA/H/C/002706/WS1795/0043; EKLIRA GENUAIR (CAP) - EMEA/H/C/002211/WS1795/0043**

Applicant: AstraZeneca AB

PRAC Rapporteur: Adam Przybyłkowski

Scope: Submission of the final report from study D6570R00002 (listed as a category 3 study in the RMP): a descriptive, non-interventional, multinational European cohort study of new users of aclidinium, aclidinium/formoterol, and other selected chronic obstructive pulmonary disease (COPD) medications to describe the characteristics and patterns of use. As a consequence, the following safety concerns listed as missing information in the RMP are removed: ‘safety in patients with hepatic or severe renal impairment’, ‘safety in patients with benign hyperplasia or urinary retention’ and ‘use in pregnancy or lactation’. The RMP (version 8.0) is updated accordingly

**Action:** For adoption of PRAC Assessment Report

---

15 In accordance with Article 107p-q of Directive 2001/83/EC
16 In accordance with Article 61a (6) of Regulation (EC) No 726/2004, in line with the revised variations regulation for any submission as of 4 August 2013
7.4.2. Acilidinium, formoterol fumarate dihydrate - BRIMICA GENUAIR (CAP) - EMEA/H/C/003969/WS1794/0029; DUAKLIR GENUAIR (CAP) - EMEA/H/C/003745/WS1794/0029

Applicant: AstraZeneca AB

PRAC Rapporteur: Adam Przybylkowski

Scope: Submission of the final report from study D6570R00002 (listed as a category 3 study in the RMP): a descriptive, non-interventional, multinational European cohort study of new users of aclidinium, aclidinium/formoterol, and other selected chronic obstructive pulmonary disease (COPD) medications to describe the characteristics and patterns of use. As a consequence, the following safety concerns listed as missing information in the RMP are removed 'safety in patients with hepatic or severe renal impairment', 'safety in patients with benign hyperplasia or urinary retention' and 'use in pregnancy or lactation'. The RMP (version 5.0) is updated accordingly

Action: For adoption of PRAC Assessment Report

7.4.3. Baricitinib - OLUMIANT (CAP) - EMEA/H/C/004085/II/0017

Applicant: Eli Lilly Nederland B.V.

PRAC Rapporteur: Adam Przybylkowski

Scope: Submission of the final report from study I4V-MC-B010 (listed as a category 3 study in the RMP): an observational, multinational cross-sectional survey amongst rheumatologists to assess the effectiveness of the risk minimisation measures (RMM) for Olumiant (baricitinib). The RMP (version 9.2) is updated accordingly. The MAH took the opportunity to remove from the RMP three safety concerns listed as missing information namely 'use in combination with biologic disease-modifying anti-rheumatic drugs (bDMARDs) or with other Janus kinase (JAK) inhibitors', 'use in patients with severe hepatic impairment', 'effect on fertility, on pregnancy and the foetus', and 'use in breastfeeding' as requested in the conclusions of variation II/006 finalised in July 2018

Action: For adoption of PRAC Assessment Report

7.4.4. Everolimus - AFINITOR (CAP) - EMEA/H/C/001038/WS1923/0068; VOTUBIA (CAP) - EMEA/H/C/002311/WS1923/0067

Applicant: Novartis Europharm Limited

PRAC Rapporteur: Martin Huber

Scope: Submission of the final clinical study report (CSR) for study CRAD001MIC03 (TOSCA): an international disease registry collecting data on manifestations, interventions and outcomes in patients with tuberous sclerosis complex (TSC). The RMP (version 15.0) is updated accordingly and in line with the conclusions of variation WS1671 adopted in October 2019

Action: For adoption of PRAC Assessment Report
7.4.5.  
**Ledipasvir, sofosbuvir - HARVONI (CAP) - EMEA/H/C/003850/WS1915/0091; sofosbuvir, velpatasvir - EPCLUSA (CAP) - EMEA/H/C/004210/WS1915/0051; sofosbuvir, velpatasvir, voxilaprevir - VOSEVI (CAP) - EMEA/H/C/004350/WS1915/0043**

Applicant: Gilead Sciences Ireland UC  
PRAC Rapporteur: Ana Sofia Diniz Martins  
Scope: Submission of the final report from study GS-US-248-0123 (listed as a category 3 study in the RMP): a long-term observational follow-up registry of subjects who did not achieve sustained virologic response in Gilead-sponsored trials in subjects with chronic hepatitis C infection. The RMPs (Harvoni version 7.1, Epclusa version 6.1, Vosevi version 3.1) are updated accordingly  
**Action:** For adoption of PRAC Assessment Report

7.4.6.  
**Mirabegron - BETMIGA (CAP) - EMEA/H/C/002388/II/0033**

Applicant: Astellas Pharma Europe B.V.  
PRAC Rapporteur: Maria del Pilar Rayon  
Scope: Submission of the final study report for study 178-CL-114: an evaluation of cardiovascular events in users of mirabegron and other treatments for overactive bladder  
**Action:** For adoption of PRAC Assessment Report

7.4.7.  
**Teriparatide - FORSTEO (CAP) - EMEA/H/C/000425/II/0054**

Applicant: Eli Lilly Nederland B.V.  
PRAC Rapporteur: Adrien Inoubli  
Scope: Submission of the final report for the European Union (EU) component of study B3D-MC-GHBX(2.1): a registry to estimate the incidence of osteosarcoma in patients who have received treatment with Forsteo (teriparatide)  
**Action:** For adoption of PRAC Assessment Report

7.4.8.  
**Tofacitinib - XELJANZ (CAP) - EMEA/H/C/004214/II/0023**

Applicant: Pfizer Europe MA EEIG  
PRAC Rapporteur: Liana Gross-Martirosyan  
Scope: Submission of the final report from study A3921205 (listed as a category 3 study in the RMP): an observational PASS within the Consortium of Rheumatology Researchers of North America (CORRONA) registry comparing rates of malignancy, cardiovascular and serious infection outcomes among patients treated for moderately to severely active rheumatoid arthritis. The RMP (version 10.1) is updated accordingly  
**Action:** For adoption of PRAC Assessment Report
7.5. **Interim results of imposed and non-imposed PASS submitted before the entry into force of the revised variation regulation**

7.5.1. **Adalimumab - IMRALDI (CAP) - EMEA/H/C/004279/MEA 003**

Applicant: Samsung Bioepis NL B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Interim report of the safety surveillance programme using the Register for Antirheumatic Therapies in Sweden (ARTIS): a national prospective, observational, uncontrolled cohort study to evaluate the risk of selected adverse events (AEs) in rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and other rheumatic disease patients treated with adalimumab

**Action:** For adoption of advice to CHMP

7.5.2. **Adalimumab - IMRALDI (CAP) - EMEA/H/C/004279/MEA 004**

Applicant: Samsung Bioepis NL B.V.

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Annual registry report of the safety surveillance programme using the Spanish Registry for Adverse Events for Biological Therapy in Rheumatic Diseases (BIOBASASER)

**Action:** For adoption of advice to CHMP

7.5.3. **Belimumab - BENLYSTA (CAP) - EMEA/H/C/002015/MEA 003.4**

Applicant: GlaxoSmithKline (Ireland) Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Submission of a biennial report for study BEL115467/HGS1006-C1113: a randomized, double-blind placebo-controlled large safety study, based on a protocol agreed with CHMP, evaluating over a minimum of one year the incidence of all-cause mortality and adverse events of special interest (AESI) in patients with systemic lupus erythematosus receiving belimumab

**Action:** For adoption of advice to CHMP

7.5.4. **Damoctocog alfa pegol - JIVI (CAP) - EMEA/H/C/004054/MEA 003.1**

Applicant: Bayer AG

PRAC Rapporteur: Menno van der Elst

Scope: MAH’s response to MEA 003 [tenth annual European Haemophilia Safety Surveillance (EUHASS) report for study 14149 (listed as a category 3 study in the RMP): evaluation of cases with adverse events (AEs) of special interest in the EUHASS registry [final clinical study report (CSR) expected in December 2021]] as per the request for supplementary information (RSI) adopted in May 2020

**Action:** For adoption of advice to CHMP
7.5.5. Dimethyl fumarate - SKILARENCE (CAP) - EMEA/H/C/002157/MEA 001.4

Applicant: Almirall S.A
PRAC Rapporteur: Annika Folin
Scope: Second annual interim results for study M-41008-40 (listed as a category 3 study in the RMP): an observational PASS in European psoriasis registers to evaluate the long-term safety of Skilarence (dimethyl fumarate) used for the treatment of patients with moderate to severe psoriasis [future due date(s): end of data collection: Q1 2027; final study report expected within a year of availability of the final data set]
Action: For adoption of advice to CHMP

7.5.6. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/MEA 007.5

Applicant: Janssen Biologics B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Fifth annual report for study CNTO148ART4001: a pregnancy research initiative to study the exposure to golimumab during pregnancy in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a review and analysis of birth outcomes from the Swedish, Danish, and Finnish medical birth registers; together with the study summary results for the 2020 interval report for study CNTO148ART4001
Action: For adoption of advice to CHMP

7.5.7. Golimumab - SIMPONI (CAP) - EMEA/H/C/000992/MEA 026.8

Applicant: Janssen Biologics B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: Fifth progress report for study MK-8259-013, the ulcerative colitis (UC) Nordic registry: a non-interventional observational longitudinal PASS of Simponi (golimumab) in the treatment of UC using Nordic national health registries
Action: For adoption of advice to CHMP

7.5.8. Sacubitril, valsartan - ENTRESTO (CAP) - EMEA/H/C/004062/MEA 004.8

Applicant: Novartis Europharm Limited
PRAC Rapporteur: Anette Kirstine Stark
Scope: MAH's response to MEA 004.7 [third interim report for study CLCZ696B2015 (PASS 3) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of Entresto/Neparvis (sacubitril/valsartan) [final report expected in Q2/2020]] as per the request for supplementary information (RSI) adopted in June 2020
Action: For adoption of advice to CHMP
7.5.9. Sacubitril, valsartan - NEPARVIS (CAP) - EMEA/H/C/004343/MEA 003.5

Applicant: Novartis Europharm Limited
PRAC Rapporteur: Anette Kirstine Stark

Scope: MAH's response to MEA 003.4 [third interim report for study CLCZ696B2015 (PASS 3) (listed as a category 3 study in the RMP): a non-interventional post-authorisation European multi-database safety study to assess the risk of myotoxicity, hepatotoxicity and acute pancreatitis in statin-exposed heart failure patients with or without concomitant use of Entresto/Neparvis (sacubitril/valsartan) [final report expected in Q2/2020]] as per the request for supplementary information (RSI) adopted in June 2020

Action: For adoption of advice to CHMP

7.5.10. Simoctocog alfa - NUWIQ (CAP) - EMEA/H/C/002813/MEA 004.6

Applicant: Octapharma AB
PRAC Rapporteur: Ulla Wändel Liminga


Action: For adoption of advice to CHMP

7.5.11. Simoctocog alfa - VIHUMA (CAP) - EMEA/H/C/004459/MEA 004.5

Applicant: Octapharma AB
PRAC Rapporteur: Ulla Wändel Liminga


Action: For adoption of advice to CHMP

7.5.12. Ulipristal acetate - ESMYA (CAP) - EMEA/H/C/002041/MEA 018.4

Applicant: Gedeon Richter Plc.
PRAC Rapporteur: Annika Folin

Scope: MAH’s response to MEA 018.3 [fourth yearly progress report for study PGL14-001: a prospective, multinational, multicentre, non-interventional study to evaluate the long-term safety of Esmya (ulipristal acetate) in particular the endometrial safety and the current prescription and management patterns of Esmya (ulipristal acetate) in a long-term treatment setting [final clinical study report (CSR) expected in 2023]] as per the request for supplementary information (RSI) adopted in June 2020

Action: For adoption of advice to CHMP
7.5.13. Vedolizumab - ENTYVIO (CAP) - EMEA/H/C/002782/MEA 001.1

Applicant: Takeda Pharma A/S

PRAC Rapporteur: Adam Przybylkowski

Scope: MAH’s response to MEA 001 [interim analysis report for study MLN-0002-401 (listed as a category 3 study in the RMP): an international prospective, observational, cohort safety study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s disease [final clinical study report (CSR) expected in June 2022]] as per the request for supplementary information (RSI) adopted in July 2020

Action: For adoption of advice to CHMP

7.6. Others

None

7.7. New Scientific Advice

None

7.8. Ongoing Scientific Advice

None

7.9. Final Scientific Advice (Reports and Scientific Advice letters)

None

8. Renewals of the marketing authorisation, conditional renewal and annual reassessments

8.1. Annual reassessments of the marketing authorisation

8.1.1. Cerliponase alfa - BRINEURA (CAP) - EMEA/H/C/004065/S/0028 (without RMP)

Applicant: BioMarin International Limited

PRAC Rapporteur: Ulla Wändel Liminga

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP

8.1.2. Galsulfase - NAGLAZYME (CAP) - EMEA/H/C/000640/S/0083 (without RMP)

Applicant: BioMarin International Limited

PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: Annual reassessment of the marketing authorisation

Action: For adoption of advice to CHMP
8.1.3. **Nelarabine - ATRIANCE (CAP) - EMEA/H/C/000752/S/0051 (without RMP)**

Applicant: Novartis Europharm Limited  
PRAC Rapporteur: Hans Christian Siersted  
Scope: Annual reassessment of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.1.4. **Smallpox vaccine (live modified vaccinia virus Ankara) - IMVANEX (CAP) - EMEA/H/C/002596/S/0054 (without RMP)**

Applicant: Bavarian Nordic A/S  
PRAC Rapporteur: Brigitte Keller-Stanislawski  
Scope: Annual reassessment of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.1.5. **Vestronidase alfa - MEPSEVII (CAP) - EMEA/H/C/004438/S/0017 (without RMP)**

Applicant: Ultragenyx Germany GmbH  
PRAC Rapporteur: Eva Segovia  
Scope: Annual reassessment of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.2. **Conditional renewals of the marketing authorisation**

8.2.1. **Bedaquiline - SIRTURO (CAP) - EMEA/H/C/002614/R/0040 (without RMP)**

Applicant: Janssen-Cilag International NV  
PRAC Rapporteur: Ulla Wändel Liminga  
Scope: Conditional renewal of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.2.2. **Obeticholic acid - OCALIVA (CAP) - EMEA/H/C/004093/R/0023 (without RMP)**

Applicant: Intercept Pharma International Limited  
PRAC Rapporteur: Liana Gross-Martirosyan  
Scope: Conditional renewal of the marketing authorisation  
**Action:** For adoption of advice to CHMP

8.3. **Renewals of the marketing authorisation**

8.3.1. **Albutrepenonacog alfa - IDELVION (CAP) - EMEA/H/C/003955/R/0047 (without RMP)**

Applicant: CSL Behring GmbH  
PRAC Rapporteur: Menno van der Elst
8.3.2. Amlodipine, valsartan - AMLODIPINE-VALSARTAN MYLAN (CAP) - EMEA/H/C/004037/R/0008 (with RMP)

Applicant: Mylan S.A.S
PRAC Rapporteur: Anette Kirstine Stark
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.3. Apixaban - ELIQUIS (CAP) - EMEA/H/C/002148/R/0077 (without RMP)

Applicant: Bristol-Myers Squibb / Pfizer EEIG
PRAC Rapporteur: Menno van der Elst
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.4. Emtricitabine, rilpivirine, tenofovir alafenamide - ODEFSEY (CAP) - EMEA/H/C/004156/R/0049 (with RMP)

Applicant: Gilead Sciences Ireland UC
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.5. Emtricitabine, tenofovir alafenamide - DESCOVY (CAP) - EMEA/H/C/004094/R/0051 (without RMP)

Applicant: Gilead Sciences Ireland UC
PRAC Rapporteur: Ana Sofia Diniz Martins
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.6. Inflixiham - FLIXABI (CAP) - EMEA/H/C/004020/R/0064 (without RMP)

Applicant: Samsung Bioepis NL B.V.
PRAC Rapporteur: Ulla Wändel Liminga
Scope: 5-year renewal of the marketing authorisation
Action: For adoption of advice to CHMP

8.3.7. Migalastat - GALAFOLD (CAP) - EMEA/H/C/004059/R/0027 (with RMP)

Applicant: Amicus Therapeutics Europe Limited
PRAC Rapporteur: Ulla Wändel Liminga
Scope: 5-year renewal of the marketing authorisation

**Action:** For adoption of advice to CHMP

### 9. Product related pharmacovigilance inspections

#### 9.1. List of planned pharmacovigilance inspections

None

#### 9.2. Ongoing or concluded pharmacovigilance inspections

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

#### 9.3. Others

None

### 10. Other safety issues for discussion requested by the CHMP or the EMA

#### 10.1. Safety related variations of the marketing authorisation

None

#### 10.2. Timing and message content in relation to Member States’ safety announcements

None

#### 10.3. Other requests

None

#### 10.4. Scientific Advice

None

### 11. Other safety issues for discussion requested by the Member States

#### 11.1. Safety related variations of the marketing authorisation

None
11.2. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

None

12.2. Coordination with EMA Scientific Committees or CMDh-v

None

12.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

None

12.4. Cooperation within the EU regulatory network

12.4.1. Coronavirus (COVID-19) pandemic - update

Action: For discussion

12.4.2. Coronavirus (COVID-19) pandemic – pharmacovigilance initiatives: preparedness plan and coverage data gathering

Action: For discussion

12.4.3. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) steering group – Call for expression of interest for a PRAC representative

Action: For discussion

12.5. Cooperation with International Regulators

None

12.6. Contacts of the PRAC with external parties and interaction with the Interested Parties to the Committee

None

12.7. PRAC work plan

None
12.8. **Planning and reporting**

12.8.1. **EU Pharmacovigilance system – quarterly workload measures and performance indicators – Q3 2020 and predictions**

*Action*: For discussion

12.9. **Pharmacovigilance audits and inspections**

12.9.1. **Pharmacovigilance systems and their quality systems**

None

12.9.2. **Pharmacovigilance inspections**

None

12.9.3. **Pharmacovigilance audits**

None

12.10. **Periodic safety update reports (PSURs) & Union reference date (EURD) list**

12.10.1. **Periodic safety update reports**

None

12.10.2. **Granularity and Periodicity Advisory Group (GPAG)**

PRAC lead: Menno van der Elst, Maia Uusküla

*Action*: For discussion

12.10.3. **PSURs repository**

None

12.10.4. **Union reference date list – consultation on the draft list**

*Action*: For adoption

12.10.5. **Union reference date (EURD) list: EURD tool - update**

PRAC lead: Menno van der Elst

*Action*: For adoption
12.11. **Signal management**


PRAC lead: Menno van der Elst

**Action:** For discussion

12.12. **Adverse drug reactions reporting and additional reporting**

12.12.1. **Management and reporting of adverse reactions to medicinal products**

None

12.12.2. **Additional monitoring**

None

12.12.3. **List of products under additional monitoring – consultation on the draft list**

**Action:** For adoption

12.13. **EudraVigilance database**

12.13.1. **Activities related to the confirmation of full functionality**

None


**Action:** For discussion


PRAC lead: Jean-Michel Dogné, Birgitta Grundmark, Brigitte Keller-Stanislawski, Anette Kirstine Stark, Sabine Straus, Menno van der Elst, Ulla Wändel Liminga

**Action:** For adoption

12.14.2. **Risk management systems**

None

12.14.3. **Tools, educational materials and effectiveness measurement of risk minimisations**

None
12.15. **Post-authorisation safety studies (PASS)**

12.15.1. **Post-authorisation Safety Studies – imposed PASS**

None

12.15.2. **Post-authorisation Safety Studies – non-imposed PASS**

None

12.16. **Community procedures**

12.16.1. **Referral procedures for safety reasons**

None

12.17. **Renewals, conditional renewals, annual reassessments**

None

12.18. **Risk communication and transparency**

12.18.1. **Public participation in pharmacovigilance**

None

12.18.2. **Safety communication**

None

12.19. **Continuous pharmacovigilance**

12.19.1. **Incident management**

None

12.20. **Others**

12.20.1. **Good Pharmacovigilance Practice (GVP) - update on GVP status overview – planning for 2021**

**Action:** For discussion

12.20.2. **Strategy on measuring the impact of pharmacovigilance – PRAC interest group (IG)**

**Impact – Revised process for prioritising impact research topics**

PRAC lead: Antoine Pariente

**Action:** For discussion

13. **Any other business**
14. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WCO0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks.

The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals may be required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.

The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)
(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine’s authorisation. PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 9 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/